Alexandre Butelet, Stéphanie Poulain, Emmanuelle Jeanpierre, Micha Srour, Morgane Nudel, Paul Chauvet, Anne Bauters, Sophie Susen, Annabelle Dupont, Marie de Charette
Ibrutinib, a first-class Bruton tyrosine kinase inhibitor, is known to be associated with adverse bleeding events and has been recently approved for the treatment of relapse Waldenström macroglobulinemia (WM). Here, we report the exhaustive clinical and biological follow-up of 2 patients treated by ibrutinib alone in the context of relapsed WM with an acquired von Willebrand syndrome (AVWS) complication. In two cases, ibrutinib has been shown to be quickly efficient and safe for treating both AVWS and its underlying condition the WM, without bleeding complications...
December 2022: Leukemia & Lymphoma